🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9 results for “Orion Laboratories Pty.” Clear

  1. Arazasetron besylate

    Orion Laboratories Pty.

    Cisplatine induced hearing loss

    phase 2 small molecule active

    1 trial

  2. MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

    Orion Laboratories Pty.

    Metastatic castration-resistant prostate cancer.

    phase 2 small molecule active

    1 trial

  3. ODM-111 Placebo, Para-Tabs 500 mg tabletti, ODM-111, ODM-111

    Orion Laboratories Pty.

    Chronic Pain due to Ostheoarthritis of the knee

    phase 2 small molecule active

    1 trial

  4. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, GEMCITABINE, IPILIMUMAB, SOTORASIB, ODM-212 5 mg coated tablet, ODM-212 40 mg coated tablet

    Orion Laboratories Pty.

    Neoplasms benign malignant and unspecified (incl. cysts and polyps)

    phase 2 small molecule active

    1 trial

  5. Para-Tabs 500 mg tabletti, ODM-111 Placebo, ODM-111, ODM-111

    Orion Laboratories Pty.

    CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY

    phase 2 small molecule active

    1 trial

  6. SENS-401 (R-Azasetron Besylate)

    Orion Laboratories Pty.

    Hearing Loss

    phase 2 small molecule completed

    1 trial

  7. Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion Laboratories Pty.

    Parkinson disease

    phase 1 other active

    1 trial

  8. Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion Laboratories Pty.

    Parkinson desease

    phase 1 other active

    1 trial

  9. Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects

    Orion Laboratories Pty.

    short-term treatment of insomnia

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources